Sputnik V, COVID-19 vaccine developed by Russia
Russian Direct Investment Fund (RDIF) announced their agreement with Indian pharma company Hetero to produce over 100 million doses of Sputnik V vaccine per year in India. The production of the Russian COVID-19 vaccine is expected to start in the beginning of 2021.
Earlier this week, Russia’s sovereign wealth fund announced via press release that the vaccine claimed an “interim efficacy” of 91.4% from its ongoing phase-3 trials. Russia also announced that Sputnik V vaccine will be priced at $10 per dose on international markets, costing less than some other registered COVID-19 vaccines. Human trials are also scheduled in India with Dr. Reddy’s as per a previous agreement between the companies.
The uniqueness of the Russian vaccine lies in the use of two different vectors based on the human adenovirus, which the makers claim allows for a stronger and longer-term immune response.
Currently, Phase III clinical trials are approved and are ongoing in Belarus, the UAE, Venezuela and other countries. Phase II-III trials are ongoing in India.
“We are delighted to announce the agreement between RDIF and Hetero that will pave the way to the production of the safe and highly effective Sputnik V vaccine on Indian soil. Thanks to our cooperation with Hetero, we will be able to significantly increase production capacity and provide people of India with an efficient solution in this challenging period of the pandemic,” said Kirill Dmitriev, CEO of the Russian Direct Investment Fund.
“We are pleased to collaborate with RDIF as a manufacturing partner for the most anticipated Sputnik V vaccine for the treatment of COVID-19. While we look forward to the clinical trial results in India, we believe that manufacturing the product locally is crucial to enable swift access to patients,” B. Murali Krishna Reddy, Director – International Marketing, Hetero Labs Limited said.